Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction

Inclusion Criteria:

• Age ≥18 years

• Patients with histologically confirmed breast cancer with indication of mastectomyor surgery with mastectomy performed

• Indication of wall chest radiation after mastectomy

• Patient's agreement to receive or having had an immediate breast reconstruction byimplant in one or two steps, with or without a dermal or synthetic matrix (dependingon the habits of the center)

• Performance Status 0-1

• Consent signed before any study procedure

• Patient geographically accessible for follow-up

• Affiliated to the French national social security system

Exclusion Criteria:

• Breast reconstruction with flap

• Inflammatory breast cancer (cT4d)

• Skin or parietal breast cancer (cT4 a, b or c)

• Metastatic patients

• Patients with bilateral breast cancer

• History of homolateral breast cancer treated with radiotherapy

• History of contralateral breast cancer

• Pregnant or breastfeeding women

• Legal incapacity or physical, psychological or mental status interfering with thepatient's ability to sign the informed consent

• Participation in an interventional clinical study or planned participation duringstudy up to 12 months post-radiotherapy